Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 260,000 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $18.23, for a total value of $4,739,800.00. Following the transaction, the director owned 5,144,998 shares in the company, valued at $93,793,313.54. This represents a 4.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.
Vor Biopharma Trading Down 9.9%
Shares of VOR stock opened at $16.27 on Tuesday. The business's 50 day moving average is $14.25 and its two-hundred day moving average is $17.35. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The company has a market capitalization of $794.79 million, a P/E ratio of -0.04 and a beta of 1.92.
Analyst Ratings Changes
Several research analysts have weighed in on VOR shares. Wall Street Zen upgraded Vor Biopharma from a "strong sell" rating to a "hold" rating in a research note on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. Wedbush lifted their target price on Vor Biopharma to $15.00 and gave the company a "neutral" rating in a research note on Tuesday, March 31st. TD Cowen started coverage on Vor Biopharma in a research note on Wednesday, December 17th. They issued a "buy" rating on the stock. Finally, Citigroup started coverage on Vor Biopharma in a research note on Friday, January 9th. They issued a "buy" rating and a $50.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $50.67.
Read Our Latest Stock Analysis on VOR
Institutional Trading of Vor Biopharma
Several hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at approximately $36,000. Bank of America Corp DE lifted its holdings in shares of Vor Biopharma by 679.3% in the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company's stock valued at $232,000 after buying an additional 4,144 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Vor Biopharma in the 3rd quarter valued at approximately $230,000. BNP Paribas Financial Markets lifted its holdings in shares of Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock valued at $296,000 after buying an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Vor Biopharma in the 3rd quarter valued at approximately $304,000. 97.29% of the stock is owned by institutional investors and hedge funds.
About Vor Biopharma
(
Get Free Report)
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
